HC Wainwright Issues Positive Forecast for Sensus Healthcare (NASDAQ:SRTS) Stock Price

Sensus Healthcare (NASDAQ:SRTS) had its price target hoisted by HC Wainwright from $11.00 to $12.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a buy rating on the stock. HC Wainwright also issued estimates for Sensus Healthcare’s Q1 2025 earnings at $0.11 EPS, Q2 2025 earnings at $0.07 EPS, Q3 2025 earnings at $0.10 EPS, Q4 2025 earnings at $0.16 EPS and FY2025 earnings at $0.44 EPS.

A number of other equities research analysts also recently issued reports on SRTS. Lake Street Capital initiated coverage on shares of Sensus Healthcare in a research report on Friday, January 31st. They issued a “buy” rating and a $18.00 price objective for the company. Maxim Group upped their price objective on shares of Sensus Healthcare from $12.00 to $14.00 and gave the stock a “buy” rating in a research report on Friday, November 15th.

Sensus Healthcare Price Performance

SRTS opened at $5.65 on Monday. Sensus Healthcare has a fifty-two week low of $2.91 and a fifty-two week high of $9.33. The company’s 50-day moving average is $7.28 and its 200 day moving average is $6.88. The firm has a market capitalization of $92.60 million, a PE ratio of 14.13 and a beta of 1.24.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%. As a group, analysts expect that Sensus Healthcare will post 0.71 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC grew its position in shares of Sensus Healthcare by 8.5% during the 3rd quarter. Geode Capital Management LLC now owns 146,404 shares of the company’s stock valued at $849,000 after acquiring an additional 11,525 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Sensus Healthcare by 128.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 166,590 shares of the company’s stock valued at $888,000 after acquiring an additional 93,511 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Sensus Healthcare during the 2nd quarter valued at approximately $156,000. XTX Topco Ltd grew its position in shares of Sensus Healthcare by 76.0% during the 3rd quarter. XTX Topco Ltd now owns 31,530 shares of the company’s stock valued at $183,000 after acquiring an additional 13,619 shares during the period. Finally, Truvestments Capital LLC bought a new position in Sensus Healthcare in the 3rd quarter worth approximately $32,000. 25.30% of the stock is owned by institutional investors.

About Sensus Healthcare

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.